Annual report of the Australian Gonococcal Surveillance Programme, 2008
DOI:
https://doi.org/10.33321/cdi.2009.33.29Keywords:
antimicrobial resistance, disease surveillance, gonococcal infection, Neisseria gonorrhoeaeAbstract
The Australian Gonococcal Surveillance Programme is funded by the Federal health department to provide laboratory analysis of gonococcal isolates in Australia. There were 3,192 gonococcal isolates referred to or else isolated in AGSP laboratories in 2008, little changed overall from the 3,103 examined in 2007. The source and site of infection of these isolates are shown in Table 1. Eight hundred and fifty-seven gonococci (27% of the Australian total) were isolated in New South Wales, 567 (17.8%) in Victoria, 542 (17%) in Queensland, 410 (12.8%) in Western Australia, 403 (12.6%) in the Northern Territory, and 391 (12.3%) in South Australia, with small numbers in Tasmania (13) and the Australian Capital Territory (9). Numbers decreased in New South Wales (from 973), Victoria (from 625) and Queensland (from 542) from those reported in 2007, but increased from 366 in Western Australia and 240 in South Australia.
Downloads
References
Tapsall J. Antibiotic resistance in Neisseria gonorrhoeae. World Health Organization, Geneva. 2001. WHO/CDS/CSR/DRS/2001.3. Available from: http://www.who.int/csr/resources/publications/drugresist/WHO_CDS_CSR_DRS_2001_3/en/
Tapsall JW, Limnios EA, Murphy DM on behalf of the Australian Gonococcal Surveillance Programme. An analysis of trends in antimicrobial resistance in Neisseria gonorrhoeae isolated in Australia, 1997–2006. J Antimicrob Chemother 2008;61(1):150–155.
Tapsall JW. Implications of current recommendations for third-generation cephalosporin use in the WHO Western Pacific region following the emergence of multi-resistant gonococci. Sex Transm Infect 2009; 85(4):256-258.
Yokoi S, Deguchi T, Ozawa T, Yasuda M, Ito S, Kubota Y, et al. Threat to cefixime treatment for gonorrhea. Emerg. Infect Dis 2007;13(8):1275–1277.
Lo JY, Ho KM, Leung AO, Tiu FS, Tsang GK, Lo AC, et al. Ceftibuten resistance and treatment failure in gonococcal infection. Antimicrob. Agents Chemother 2008;52(10):3564–3567.
Tapsall JW, Read P, Carmody C, Bourne C, Ray S, Limnios A, et al. Two cases of failed ceftriaxone treatment in pharyngeal gonorrhoea verified by molecular microbiological methods. J Med Microbiol 2009;58(5):683–687.
Tapsall JW. Monitoring antimicrobial resistance for public health action. Commun Dis Intell 2003,27(Suppl):S70–S74.
Workowski KA, Berman SM, Douglas Jr JM. Emerging antimicrobial resistance in Neisseria gonorrhoeae: urgent need to strengthen prevention strategies. Ann Intern Med 2008;148(8):606–613.
Australian Gonococcal Surveillance Programme. Penicillin sensitivity of gonococci in Australia: development of an Australian Gonococcal Surveillance Programme. Br J Vener Dis 1984;60(4):226–230.
Australian Gonococcal Surveillance Programme. Annual report of the Australian Gonococcal Surveillance Programme, 2007. Commun Dis Intell 2008;32(2):227–231.
Tapsall J, and members of the National Neisseria Network of Australia. Antimicrobial testing and applications in the pathogenic Neisseria. In: Merlino J, ed. Antimicrobial susceptibility testing: methods and practices with an Australian perspective. Australian Society for Microbiology, Sydney, 2004. pp 175–188.
Australian Gonococcal Surveillance Programme. Use of a quality assurance scheme in a long-term multicentric study of antibiotic susceptibility of Neisseria gonorrhoeae. Genitourin Med 1990,66:437–444.
WHO Collaborating Centre for STD, Sydney. Rationale and applications for the current (2008) WHO panel of Neisseria gonorrhoeae for antimicrobial resistance surveillance for public health purposes, and instructions for their use. Technical document D007-0408-1#1 2008.
Unemo M, Fasth O, Fredlund H, Limnios A, Tapsall J. Phenotypic and genetic characterization of the 2008 WHO Neisseria gonorrhoeae reference strain panel intended for global quality assurance and quality control of gonococcal antimicrobial resistance surveillance for public health purposes. J Antimicrob Chemother 2009;63(6):1142–1151.
Tapsall JW. Neisseria gonorrhoeae and emerging resistance to extended spectrum cephalosporins. Curr Op Infect Dis 2009;22(1):87–89.
Zhao S, Duncan, M, Tomberg J, Davies C, Unemo M, Nicholas RA. Genetics of chromosomally mediated intermediate resistance to ceftriaxone and cefixime in Neisseria gonorrhoeae. Antimicrob Agents Chemother 2009 53(9):3744-3751.
Whiley D, Bates J, Limnios A, Nissen M, Tapsall J, Sloots T. Use of a novel screening PCR indicates presence of Neisseria gonorrhoeae isolates with a mosaic penA gene sequence in Australia. Pathology 2007;39(4):445–446.
Whiley DM, Limnios EA, Ray S, Sloots TP, Tapsall JW. Diversity of penA alterations and subtypes in Neisseria gonorrhoeae strains from Sydney, Australia, that are less susceptible to ceftriaxone. Antimicrob Agents Chemother 2007;51(9):3111–3116.
Newman LM, Moran JS, Workowaski KA. Update on the management of gonorrhea in adults in the United States. Clin Infect Dis 2007;44(Suppl 3):S84–S101.
Tapsall JW. Multi-resistant Neisseria gonorrhoea. CMAJ 2009;180:268–269.
Downloads
Published
How to Cite
Issue
Section
Categories
License
Copyright (c) 2009 Communicable Diseases Intelligence
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
